AAAAAA

   
Results: 1-25 | 26-33
Results: 1-25/33
Subtype-specific problems with qualitative Amplicor HIV-1 DNA PCR test
Authors: Bogh, M Machuca, R Gerstoft, J Pedersen, C Obel, N Kvinesdal, B Nielsen, H Nielsen, C
Citation: M. Bogh et al., Subtype-specific problems with qualitative Amplicor HIV-1 DNA PCR test, J CLIN VIRO, 20(3), 2001, pp. 149-153
High levels of CD8-positive lymphocytes expressing CD45R0, granzyme B, andKappa i-67 in lymph nodes of HIV-infected individuals are not associated with increased mortality
Authors: Espersen, C Pakkenberg, B Harder, E Pallesen, G Gerstoft, J Pedersen, BK Ullum, H
Citation: C. Espersen et al., High levels of CD8-positive lymphocytes expressing CD45R0, granzyme B, andKappa i-67 in lymph nodes of HIV-infected individuals are not associated with increased mortality, AIDS RES H, 17(4), 2001, pp. 287-293
MC148 encoded by human molluscum contagiosum poxvirus is an antagonist forhuman but not murine CCR8
Authors: Luttichau, HR Gerstoft, J Schwartz, TW
Citation: Hr. Luttichau et al., MC148 encoded by human molluscum contagiosum poxvirus is an antagonist forhuman but not murine CCR8, J LEUK BIOL, 70(2), 2001, pp. 277-282
T-cell mean telomere lengths changes in treatment naive HIV-infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART
Authors: Aladdin, H Von Essen, M Schjerling, P Katzenstein, T Gerstoft, J Skinhoj, P Pedersen, BK Ullum, H
Citation: H. Aladdin et al., T-cell mean telomere lengths changes in treatment naive HIV-infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART, SC J IMMUN, 54(3), 2001, pp. 301-305
Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients
Authors: Aladdin, H Larsen, CS Schjerling, P Moller, BK Buhl, MR Gerstoft, J Pedersen, BK Ullum, H
Citation: H. Aladdin et al., Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients, SC J IMMUN, 53(3), 2001, pp. 315-319
Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA
Authors: Clumeck, N Goebel, F Rozenbaum, W Gerstoft, J Staszewski, S Montaner, J Johnson, M Gazzard, B Stone, C Athisegaran, R Moore, S
Citation: N. Clumeck et al., Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA, AIDS, 15(12), 2001, pp. 1517-1526
HIV-1 subtypes in Denmark
Authors: Machuca, R Bogh, M Salminen, M Gerstoft, J Kvinesdal, B Pedersen, C Obel, N Nielsen, H Nielsen, C
Citation: R. Machuca et al., HIV-1 subtypes in Denmark, SC J IN DIS, 33(9), 2001, pp. 697-701
Comparison of p-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir
Authors: Roge, BT Katzenstein, TL Gerstoft, J
Citation: Bt. Roge et al., Comparison of p-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir, SC J IN DIS, 33(4), 2001, pp. 306-311
The herpesvirus 8-encoded chemokine vMIP-II, but not the poxvirus-encoded chemokine MC148, inhibits the CCR10 receptor
Authors: Luttichau, HR Lewis, IC Gerstoft, J Schwartz, TW
Citation: Hr. Luttichau et al., The herpesvirus 8-encoded chemokine vMIP-II, but not the poxvirus-encoded chemokine MC148, inhibits the CCR10 receptor, EUR J IMMUN, 31(4), 2001, pp. 1217-1220
Genotypic and phenotypic nevirapine resistance correlates with virologicalfailure during salvage therapy including abacavir and nevirapine
Authors: Jorgensen, LB Katzenstein, TL Gerstoft, J Mathiesen, LR Pedersen, C Nielsen, C
Citation: Lb. Jorgensen et al., Genotypic and phenotypic nevirapine resistance correlates with virologicalfailure during salvage therapy including abacavir and nevirapine, ANTIVIR TH, 5(3), 2000, pp. 187-194
The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals
Authors: Nielsen, SD Sorensen, TU Aladdin, H Ersboll, AK Mathiesen, L Ullum, H Gerstoft, J Nielsen, JO Pedersen, BK Nielsen, SD
Citation: Sd. Nielsen et al., The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals, SC J IMMUN, 52(3), 2000, pp. 298-303
Effects of G-CSF on telomere lengths in PBMCs from human immunodeficiency virus-infected patients: Results from a randomized, placebo-controlled trial
Authors: Aladdin, H Ullum, H Schjerling, P Jensen, MS Nielsen, SD Mathiesen, L Gerstoft, J Skinhoj, P Pedersen, BK
Citation: H. Aladdin et al., Effects of G-CSF on telomere lengths in PBMCs from human immunodeficiency virus-infected patients: Results from a randomized, placebo-controlled trial, SC J IMMUN, 52(2), 2000, pp. 212-216
Immunological and virological changes in antiretroviral naive human immunodeficiency virus infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART
Authors: Aladdin, H Ullum, H Katzenstein, T Gerstoft, J Skinhoj, P Pedersen, BK
Citation: H. Aladdin et al., Immunological and virological changes in antiretroviral naive human immunodeficiency virus infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART, SC J IMMUN, 51(5), 2000, pp. 520-525
Effects of subcutaneous interleukin-2 therapy on phenotype and function ofperipheral blood mononuclear cells in human immunodeficiency virus infected patients
Authors: Aladdin, H Larsen, CS Moller, BK Ullum, H Buhl, MR Gerstoft, J Skinhoj, P Pedersen, BK
Citation: H. Aladdin et al., Effects of subcutaneous interleukin-2 therapy on phenotype and function ofperipheral blood mononuclear cells in human immunodeficiency virus infected patients, SC J IMMUN, 51(2), 2000, pp. 168-175
AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients
Authors: Gartland, M Gerstoft, J Goebel, F Clumeck, N Cooper, DA Gatell, J Gazzard, B Gerstoft, J Goebel, F Lange, J Montaner, J Reiss, P Rozenbaum, W Vella, S Beveridge, A Cooper, DA Duncombe, C Gold, J Haberl, M Clumeck, N Luyts, D Montaner, J Rachlis, A Marina, R Gerstoft, J Wandall, JH Elbrond, B Molina, JM Pialloux, G Rozenbaum, W Beauvais, L Goebel, FD Staszewski, S Bruns, I Hug, M Reiss, P Lange, J Frissen, PHJ van der Ende, ME Bosboom, M Baas, C Milazzo, F Moroni, M Panebianco, R Clotet, B Artigas, JMG Gonzalez-Lahoz, J Leal, M Rodriguez-Lopo, C Gandarias, B Gazzard, B Johnson, M McKinley, S Page, V Watkins, K Sandstrom, E Belsey, E Darbyshire, J Chodakewitz, J Isaacs, R Jonas, L Meibohm, A Coughlan, M Fiddian, P Gartland, M Harrigan, R Larder, B Maguire, M Millard, J Moore, S Patel, K Shortino, D Tisdale, M Vafidis, I Yeo, J
Citation: M. Gartland et al., AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients, AIDS, 14(4), 2000, pp. 367-374
Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit
Authors: Reiss, P Vella, S Cooper, D Lange, J Gartland, M Gerstoft, J Goebel, F Larder, B Clumeck, N Gatell, J Gazzard, B Rozenbaum, W Rae, S O'Shaughnessy, MV Robinson, P Harrigan, PR Raboud, J Alexander, CS Maguire, M Montaner, JS
Citation: P. Reiss et al., Highly active antiretroviral therapy including protease inhibitors does not confer a unique CD4 cell benefit, AIDS, 14(10), 2000, pp. 1383-1388
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues
Authors: Van Vaerenbergh, K Van Laethem, K Albert, J Boucher, CAB Clotet, B Floridia, M Gerstoft, J Hejdeman, B Nielsen, C Pannecouque, C Perrin, L Pirillo, MF Ruiz, L Schmit, JC Schneider, F Schoolmeester, A Schuurman, R Stellbrink, HJ Stuyver, L Van Lunzen, J Van Remoortel, B Van Wijngaerden, E Vella, S Witvrouw, M Yerly, S De Clercq, E Desmyter, J Vandamme, AM
Citation: K. Van Vaerenbergh et al., Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues, ANTIM AG CH, 44(8), 2000, pp. 2109-2117
Prognostic value of single measurements of beta-2-microglobulin, immunoglobulin a in HIV disease after controlling for CD4 lymphocyte counts and plasma HIV RNA levels
Authors: Ullum, H Lepri, AC Katzenstein, TL Phillips, AN Skinhoj, P Gerstoft, J Pedersen, BK
Citation: H. Ullum et al., Prognostic value of single measurements of beta-2-microglobulin, immunoglobulin a in HIV disease after controlling for CD4 lymphocyte counts and plasma HIV RNA levels, SC J IN DIS, 32(4), 2000, pp. 371-376
The Danish protease inhibitor study: A randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection
Authors: Katzenstein, TL Kirk, O Pedersen, C Lundgren, JD Nielsen, H Obel, N Nielsen, C Mathiesen, LR Gerstoft, J
Citation: Tl. Katzenstein et al., The Danish protease inhibitor study: A randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection, J INFEC DIS, 182(3), 2000, pp. 744-750
Granulocyte colony-stimulating factor increases CD4(+) T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: Results from a randomized, placebo-controlled trial
Authors: Aladdin, H Ullum, H Nielsen, SD Espersen, C Mathiesen, L Katzenstein, TL Gerstoft, J Skinhoj, P Pedersen, BK
Citation: H. Aladdin et al., Granulocyte colony-stimulating factor increases CD4(+) T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: Results from a randomized, placebo-controlled trial, J INFEC DIS, 181(3), 2000, pp. 1148-1152
A highly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosum
Authors: Luttichau, HR Stine, J Boesen, TP Johnsen, AH Chantry, D Gerstoft, J Schwartz, TW
Citation: Hr. Luttichau et al., A highly selective CC chemokine receptor (CCR)8 antagonist encoded by the poxvirus molluscum contagiosum, J EXP MED, 191(1), 2000, pp. 171-179
Adrenaline-induced mobilization of T cells in HIV-infected patients
Authors: Sondergaard, SR Lepri, AC Ullum, H Wiis, J Hermann, CK Laursen, SB Qvist, J Gerstoft, J Skinhoj, P Pedersen, BK
Citation: Sr. Sondergaard et al., Adrenaline-induced mobilization of T cells in HIV-infected patients, CLIN EXP IM, 119(1), 2000, pp. 115-122
Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis
Authors: Katzenstein, TL Dickmeiss, E Aladdin, H Hede, A Nielsen, C Nielsen, H Jorgensen, LB Gerstoft, J
Citation: Tl. Katzenstein et al., Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis, ANN INT MED, 133(1), 2000, pp. 31-34
Presence of multiple HIV subtypes and a high frequency of subtype chimericviruses in heterosexually infected women
Authors: Iversen, AKN Learn, GH Fugger, L Gerstoft, J Mullins, JI Skinhoj, P
Citation: Akn. Iversen et al., Presence of multiple HIV subtypes and a high frequency of subtype chimericviruses in heterosexually infected women, J ACQ IMM D, 22(4), 1999, pp. 325-332
Immune function and phenotype before and after highly active antiretroviral therapy
Authors: Sondergaard, SR Aladdin, H Ullum, H Gerstoft, J Skinhoj, P Pedersen, BK
Citation: Sr. Sondergaard et al., Immune function and phenotype before and after highly active antiretroviral therapy, J ACQ IMM D, 21(5), 1999, pp. 376-383
Risultati: 1-25 | 26-33